Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 54 years~* Diagnosis of AD as defined by Hanifin and Rajka (1980) criteria for AD~* History of AD for ≥1 year~* Subjects who have a recent history of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable~* AD involvement of ≥10% body surface area at screening and baseline~* An EASI score of ≥12 at screening and 16 at baseline~* An IGA score of ≥3 at screening and at baseline~* Subjects must have applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation~Exclusion Criteria:~* Subjects for whom administration of the meningococcal vaccine provided in this trial is contraindicated or medically inadvisable, according to local label of the vaccine~* Subjects for whom administration of the tetanus, diphtheria, and pertussis vaccine provided in this trial is contraindicated or medically inadvisable, according to local label of the vaccine~* Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment~* Use of tanning beds or phototherapy within 6 weeks prior to randomization~* Treatment with systemic immunosuppressive/immunomodulating medications and/or systemic corticosteroids within 4 weeks prior to randomization~* Treatment with the topical medications topical corticosteroids (TCS), topical calcineurin inhibitor (TCI) or phosphodiesterase 4 (PDE-4) inhibitor within 2 weeks prior to randomization~* Receipt of any vaccine (except influenza virus vaccines) within 3 months prior to screening, any meningococcal vaccine within 1 year prior to screening, or any tetanus-, diphtheria-, or pertussis-containing vaccine within 5 years prior to screening~* Receipt of any marketed (i.e. immunoglobulin, anti-IgE) or investigational biologic agent, including dupilumab~* History of any active skin infection within 1 week prior to randomization~* History of a clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 54 Years
- Healthy Volunteers: f

Study Arms:
- Tralokinumab (Type: EXPERIMENTAL): Week 0 to 16:~Tralokinumab will be given as subcutaneous injections.~Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (dummy treatment) will be given as subcutaneous injections.~Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete